Healthcare knowledge firms Atropos Well being and Seqster are focusing on underrepresented populations in medical trials after the 2 firms shaped a strategic partnership to ascertain turnkey affected person registries.
Atropos, a supplier of on-demand proof from real-world knowledge to healthcare and life science organisations, will present its Well being Proof Community to Seqster. Seqster, which aggregates well being knowledge from totally different sources onto a single platform, will enter longitudinal affected person knowledge.
The 2 US-headquartered firms will create turnkey affected person registries that may generate proof for medical growth. This course of normally takes as much as a yr and might value tens of millions, Atropos Well being mentioned in a 14 December press launch. The corporate added that the “speed-to-insight” of registry-based analysis the partnership gives will assist underrepresented populations.
Seqster’s CEO Ardy Arianpour mentioned: “By powering the Atropos Well being Proof Community with longitudinal affected person knowledge, we’ll be capable of save well being techniques and life science enterprises value and time on registry deployment.”
Underrepresentation of population groups is an ever-present concern in medical trials. The shortage of recruitment of racial minorities, ladies, and different teams in trials means there may be an inherent bias in design outcomes. In 2022, the US Meals and Drug Administration (FDA) issued guidance on growing underrepresented teams in trials.
Actual-world knowledge is turning into an effective way to include data from underrepresented populations within the lifecycle of a drug’s approval. England’s Nationwide Well being Service (NHS) has been utilizing it in medical trials following the framework launched by the UK’s Nationwide Institute for Well being and Care Excellence (NICE).
Entry essentially the most complete Firm Profiles
available on the market, powered by GlobalData. Save hours of analysis. Achieve aggressive edge.
Firm Profile – free
Your obtain e mail will arrive shortly
We’re assured in regards to the
high quality of our Firm Profiles. Nonetheless, we wish you to take advantage of
determination for your corporation, so we provide a free pattern you can obtain by
submitting the under kind
Seqster and Atropos Well being purpose to supply fast proof technology to each sufferers and companions. Seqster will obtain entry to Atropos Well being’s portfolio of evidence-generation instruments. This contains Geneva OS and ChatRWD, which the corporate launched in October 2023.
The generative synthetic intelligence (AI) instruments facilitate entry to a lot of current research and lively medical trial designs. Geneva OS additionally contains the Medical Analysis Acceleration for Trials (CRAFT) Emulation Toolkit, which improves trial recruitment and helps plan trial design.
Seqster isn’t the one firm to faucet Atropos Well being’s know-how. In September 2023, Johnson & Johnson’s firm Janssen Analysis & Growth signed an agreement with the healthcare knowledge firm to expedite medical growth.